-->

Tag: Targeted lung cancer therapy

Home / Targeted lung cancer therapy

Categories

Amivantamab-vmjw is approved by the USFDA for EGFR exon 20 insertion-mutated non-small cell lung cancer indications

The Food and Drug Administration approved amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) in combination with carboplatin and pemetrexed on March 1, 2024. Patients with epidermal growth factor re...
targeted-lung-cancer-therapy

Tepotinib is approved by the USFDA for metastatic non-small cell lung cancer

The Food and Drug Administration officially approved tepotinib (Tepmetko, EMD Serono, Inc.) on February 15, 2024, for adult patients with metastatic non-small cell lung cancer (NSCLC) that had mesenc...
targeted-lung-cancer-therapy

Scan the code